Chengdu Suncadia registers first Phase 1 study of small molecule HRS-8797
The healthy-volunteer trial will test safety and pharmacokinetics of HRS-8797, the sponsor's first clinical study of the compound, with a primary completion date of December 2026.
Executive Summary
- Chengdu Suncadia Medicine Co., Ltd. has registered its first clinical trial of HRS-8797, moving the small molecule from preclinical into human testing.
- The study is designed to establish safety and pharmacokinetics in healthy volunteers, the standard first step before any disease-specific testing begins.
- The sponsor brings a clean completion record across its broader pipeline, a normal baseline for launching a new early-stage program.
- HRS-8797's target and mechanism are not yet established in available records, leaving the compound's therapeutic rationale to emerge as the program advances.
The study
Chengdu Suncadia Medicine Co., Ltd. added NCT07698756 to the ClinicalTrials.gov registry on July 13, 2026, a Phase 1 study of HRS-8797 titled "A Clinical Study of HRS-8797 in Healthy Participants". The trial is not yet recruiting, is set to start July 1, 2026, and targets 74 healthy adult participants in China. The primary completion date is December 1, 2026, with full study completion anticipated by January 1, 2027. NCT07698756A Clinical Study of HRS-8797 in Healthy ParticipantsNCT07698756
The design
The trial is structured around single ascending dose, multiple ascending dose, and food-effect cohorts, standard elements of a first-in-human pharmacokinetic study. The primary endpoint measures the incidence of adverse events and serious adverse events across the dosing windows, tracked from day 1 through day 15 in the single-dose and food-effect cohorts and through day 21 in the multiple-dose cohort. Secondary endpoints capture standard pharmacokinetic parameters, including apparent clearance, area under the concentration-time curve, time to maximum plasma concentration, and maximum plasma concentration, each measured over days 1 through 19. Eligible participants are healthy men and women aged 18 to 55, screened for clinically significant abnormalities, infectious disease markers, and substance use history. NCT07698756A Clinical Study of HRS-8797 in Healthy ParticipantsNCT07698756
Sponsor track record
Chengdu Suncadia Medicine Co., Ltd. has completed 12 of its 12 resolved trials with no terminations, and currently runs a broader pipeline of 21 trials spanning recruiting, not-yet-recruiting, and active phases. That completion history is a normal baseline for a sponsor launching an early-stage program and does not, on its own, say anything about how HRS-8797 will perform.
What remains open
HRS-8797's target and mechanism of action are not established in available records, and no competitor trial sharing a comparable target or drug class was identified. That leaves the compound's therapeutic direction, what disease area it is intended to treat, to be defined by later disclosures rather than by this healthy-volunteer safety study, which is designed only to characterize tolerability and pharmacokinetics ahead of any disease-specific testing.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.